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Medicinal compounds
Two huge waves, economic and technical,
are combining to create a robustly healthy
future for medical devices based on com-
pound semiconductor technology with
telemedicine taking a lead position for 
catastrophic disaster. 
The ESA funded telemedicine project called 
I-DISCARE went into action to help the victims
along some of the coastal areas ravaged by the
Boxing Day Tsunami. It is used to connect
mobile teams of rescue workers with hospitals
via satellite, greatly improving access to medical
advice.
On the initiative of the French Space Agency
(CNES) which paid the transport costs, three
portable telemedicine work stations were lent to
the Indian telemedicine IndoCompu-tech. Used
on the sub-continent east coast by mobile teams
of doctors and paramedics, the stations connect-
ed them with central hospitals at Lucknow,
Madras and Ahmadabad.
A further five compact data terminals were used
by mobile sanitary teams to send epidemiology,
water and nutrition data to public health insti-
tutions in New Delhi and SE coastal centres.
Doctors and paramedics equipped with GPS
capable terminals are better able to treat patients
at the scene, while still maintaining close contact
with mobile field hospitals, aid centres and refer-
ence hospitals, even if these are located outside
the country. Results ensure earlier patient identi-
fication; quicker and more traceable data collec-
tion, giving faster triage and better care.
Dr Bernard Comet of The Institute for Space
Medicine and Physiology(MEDES) and prime
contractor behind I-DISCARE said,“The quick
availability of I-DISCARE makes it an excellent
solution for these types of emergencies.”
Satellites & telemedicine
I-DISCARE is a follow-up from an earlier funded
project, DELTASS, two years ago, to prove that
satellite systems can be both cost effective and
adaptable in disaster situations, where infrastruc-
tures are partly or completely destroyed.
I-DISCARE combined MEDES, satellite service
provider Elsacom of Italy and Norway’s Centre
for Telemedicine, with a series of pilot deploy-
ments and a large demonstration in Tromsø,
Norway in October 2004.
The I-DISCARE project team presented the
results of the ESA funded project at ESA/ESTEC
Noordwijk, the Netherlands in January, but
telemedicine’s future depends on the pivotal role
played by compound devices’ enabling role in
communications.
Economic drivers
Until very recently,Western basic health care
strategy has been to cure the ailment. Several fac-
tors are forcing a change.The first is that more
baby boomers are reaching retirement. Most are
in rude health now, but the time will come when
their bodies give out - a growing ageing market.
Secondly, the efficacy of many existing drugs
seems to be dropping and the pipeline of new
ones is emptying. Big pharmaceutical companies
owe most of their profits to patent-protected,
blockbuster drugs, but many of these patents
expire soon. Cost of developing and bringing
new drugs to market is almost prohibitative.
Thirdly, obesity is a worldwide problem. More than
a third of people in developed economies are over-
weight. Costs are huge. In 2001 the US Surgeon
General estimated obesity cost the US taxpayer
$30bn/year in extra medical costs and possibly
more in lost productivity.
As a result, governments and insurance compa-
nies find old ways of providing health care 
unaffordable.The emerging strategy stresses
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ESA’s mobile telemedicine vans equipped with video and 
communications for conferencing facilities 
prevention rather than cure, and brings
plenty of markets for earning money,
keeping old fogies and young converts,
skinny, fit and mobile.
Outside telecommunications, the com-
pound semiconductor industry 
contributes to medical care in three
basic areas: research, test and diagnosis;
treatment and replacement; monitoring
and alarms. Here opto, photonic and RF
devices all play a part, with quantum
dots and nano surging ahead.
The semiconductor content of most
medical devices, particularly those used
for analysing and monitoring patients,
has risen in 50 years. Estimates of current
world markets for medical devices range
from $50bn-$120bn/year. Much of the
value is in embedded electronics.
The basic model
Despite record overweight numbers,
more people are living longer, but more
suffer chronic ailments such as coronary
heart disease, diabetes and strokes and
have to cope with aging effects: brittle
bones, poor eyesight, menopause and
memory loss.As health care costs rocket,
the search is on to reduce them.
Governments and insurance companies
respond two ways: persuading people to
adopt better eating habits; and finding
cheaper technical solutions.
These include earlier and better diagno-
sis of impending problems and the dis-
covery of more and better drugs on the
one hand, and developing cheaper, small-
er, faster prosthetic devices that substi-
tute for, or improve on, living organs.
Gross physical causes of ill health are
well-known, (smoking, lack of exercise
poor diet). But the precise interaction
between foods and cells is neither explicit
nor well-understood. However, not until
relatively recently has science had the
tools to explore these massively complex
interactions in the required detail.
A vast new subject for nutritionists is
bioavailabilty, or how the body takes up
and uses nutrients in foods and drinks.
Currently researchers are exploring these
mechanisms at a cellular or even molecu-
lar level. Of particular interest is the
influence of an individual’s DNA on the
body, first as a future health problem pre-
dictor; second as a mediator to improve
health outcomes.
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Roche Molecular System’s Cytochrome P450 test is the
first DNA microarray test to be cleared by the FDA. It
paves the way for similar microarray-based diagnostic
tests in future.
A microarray is similar to a semiconductor chip, but
instead of circuits, the chip contains millions of DNA mol-
ecules. The test uses DNA extracted from a patient’s
blood. A person’s DNA sequence is determined based on
the sequence of the probe molecule to which the DNA is
most similar. 
The new test analyses one of the genes from a family of
genes called cytochrome P450 genes. These are active in
the liver to break down certain drugs and other com-
pounds. Variations in this gene can cause a patient to
metabolise certain drugs more quickly, or more slowly
than average, or, in some cases, not at all. 
The specific enzyme from this family analysed by 
this test, cytochrome P4502D6, is important for the 
body to metabolise some common drugs including 
antidepressants, anti-psychotics, beta-blockers, and
some chemotherapy drugs. 
“The test is not intended to be a stand-alone tool to deter-
mine optimum drug dosage, but should be used along
with clinical evaluation and other tools to determine the
best treatment options for patients,” the FDA says.
Microarray & diagnosis 
Table 1: MEMS and their applications
Application Function
Drug delivery system External and implantable pumps; smart pills
Cardiology Cavity-monitoring pacemakers 
Monitoring Point of care testing - handheld blood analysers; 
online blood monitors; blood pressure monitors
Biotechnologies Liquid handling systems; Genetic tests; Therapy
Artificial organs Neural stimulator probes; Nanotexturising of surfaces 
for better biocompatibility of implants
Minimally invasive Painless ultrasonic and laser cutting tools
and precise surgery
Source: Northern Ireland Semiconductor Research Centre
The liver lab on a chip (LOAC) microarray
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Much of this work is possible due to the
use of semiconductor manufacturing
processes to develop “lab on a chip”
(LOCs) or microelectromechanical sys-
tems (MEMS).These micro-arrays are
microcapilliary systems that contain tiny
pumps, valves, dispensers and mixers
with biological and chemical binding
compounds for analysis.They can per-
form hundreds to thousands of biochemi-
cal and bioelectrical tests simultaneously,
quickly and cheaply. In some cases they
can supplement or replace mass, gas and
ion mobility spectrometers and sensors.
(Table 1).
This versatility makes them attractive in
many roles, particularly analytical work.
Analysts Frost & Sullivan estimate world
market for diagnostics at <$25bn/year.
“LOCs have immense potential in this
area,” says the firm’s Katherine Austin.
Not only that area, but in drug screening
too. It now costs upwards of $500m to
develop a new drug; only one in 10 wins
regulatory approval.Anything that 
winnows the possible from the probable
candidate drug molecules, and verifies
their efficacy, has drug barons’ approval.
This is because LOCs offer speed, cheap-
ness, precision, flexibility and virtual
ubiquity.To improve LOCs’ capabilities,
some are turning to New Hampshire-
based JPSA Laser, which offers contract
UV excimer and DPSS laser machining of
one-micron features to sub-micron toler-
ances for medical devices.These include
microarrays, sensors, nozzles, screens,
particle traps, MEMS, etc on a wide
spread of materials: semiconductors,
through polymers, ceramics to diamond.
Within our lifetimes we could have our
personal health monitors. Researchers at
the University of Illinois, Urbana-Cham-
paign have developed protein-encapsulat-
ed SW carbon nanotubes that fluoresce in
the presence of specific biomolecules.The
primary market is to help diabetics moni-
tor blood glucose levels, but the technolo-
gy could lead to new types of implantable
biological sensors, say researchers.
IBM medical systems researchers, Scott
Jenkins and Christopher Perrera describe a
scenario where all building blocks are in
place, but are presently too expensive.
Feeling poorly, you buy a gene- or protein-
based diagnostics kit from your local drug
store, take a cheek-swab or a saliva sample,
put it on the test chip in your Web-enabled
personal analyser.After incubation, raw
data goes to a reference lab which sends
results back to you by e-mail or SMS to
your mobile.The lab also sends them to
your doctor, whose diary agent schedules a
choice of appointments, or if drugs are
indicated, places an order and delivery
instruction with your local pharmacist.
Just before Christmas, the US Food &
Drug Administration (FDA) took the first
step towards making this a reality. On 23
December it approved “the first laboratory
test system that will allow physicians to
consider unique genetic information from
patients in selecting medications and
doses of medications for a wide variety of
common conditions such as cardiac dis-
ease, psychiatric disease and cancer.” The
test is the AmpliChip Cytochrome P450
genotyping test made by Roche Molecular
Systems, based on Affymetrix’s GeneChip
technology (see: Microarray & diagnosis)
The potential for semiconductor-based
tools and prosthetic organs appears
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An Rs130m ($2.9m) telemedicine
system will use satellite to connect,
doctors from some of the best hos-
pitals across the country with
patients in Jharkhand, India. 
The Jharkhand Space Application
Centre (JSAC) has proposed a
telemedicine system to help the
poor reach diagnostic facilities at
good hospitals. The Indian Space
Research Organisation will provide
satellite connectivity infrastructure
bandwidth, and VSAT facilities to
JSCA. Telemedicine is to benefit
54% of the state’s 26.91m popula-
tion living below the poverty line. 
The project, over three phases will
connect 22 district hospitals, three
video conferencing facility mobile
vans, and three medical college hos-
pitals with a master control facility
located at the state capital, Ranchi.
A specialised centre in every district
hospital will have video conferenc-
ing, telemedicine software and
hardware, communication system,
diagnostic equipment and medical
equipment facilities . 
In the US, Harvard Med School is
reputedly leading in extending
telemedicine from the existing hos-
pital to doctor link, into a doctor-
patient link to reduce in-office visits
and cut overall healthcare costs. 
At one level, doctors are sending
text-message reminders to patients,
via mobile phones and PDAs to take
their prescribed medications. 
Dr Joseph Kvedar, vice chair of der-
matalogy at Harvard Med School
notes that people are more likely to
change routine if they use tech-
nologies like mobile phones that
they have already adopted.
At another level, Motorola and
Telemedicine Partners, Harvard, is
trialling a communications hub to
monitor critically ill patients in the
home. Patients have a Nextel mobile
handset equipped with a Java
applet, a scale and a blood pressure
cuff. This sends data wirelessly by
Blue-tooth to a Website, and
viewed by physicians, to become a
monitor for congestive heart failure.
Wireless telemedicine
Figure 3: The background shows that unsung
hero C elegans roundworm. The bright green
dots are neurons. The thin green lines extending
from the neurons are axons. The inset demon-
strates where the laser ‘nanoscissor’ 
severs the axon. Photo: H. Cinar & Y. Jin  
almost untouched. Regulatory bodies
have adopted a cautious approach to
approvals, but the FDA appears to be
picking up pace. In October it approved
for human medical uses the VeriChip, an
RFID implantable chip capable of linking
up to a secure identity authentication
database. In November, Florida-based
Applied Digital Solutions, signed a distri-
bution deal with Henry Schein Inc, the
largest distributor of healthcare products
to private practices in North America and
Europe.The idea is that doctors will
“chip” their patients and link them to
their electronic patient records systems.
Light & LED repairs
The FDA followed this in January by
approving an LED-based infrared lamp
from Denver’s BioCare Systems. Infrared
light is delivered to the tissue through
144 GaAlAs LEDs with average wave-
lengths of between 880-884nm.The
device is said to relieve pain associated
with muscles in the neck, back and
joints, including sprains and arthritis.
BioCare may be onto a good thing.
Device-based pain management therapies
in the US are worth over $700m/year in
a $32bn market. Others are starting to
use low level lasers in other therapies,
including acupuncture.
Depending on laser power, visible and
near-IR photons may penetrate the skin
up to several centimetres. Light at this
frequency is known to trigger a biochem-
ical cascade within tissue cells.This “pho-
tobiomodulation” results in cell repair,
increased cell respiration, decreased
inflammation and oedema in tissues.
Clinical test have shown this “needleless
acupuncture” to be clinically effective for
carpal tunnel syndrome, neck and shoul-
der pain, wound healing and stroke paral-
ysis, as well as osteoarthritis, sports
injuries,TMJ, post-herpetic neuralgia, back
pain, bursitis, dental sensitivity, neuropa-
thy, attention deficit disorder (ADD) and
even delayed development in children.
But others are using lasers to cure halito-
sis. Chronic persistent bad breath is
sometimes caused by anaerobic respira-
tion by bacteria trapped in tonsil tissue.
Israeli doctors use lasers to vapourise the
affected tissue, and the resulting scar tis-
sue assures a permanent result.
Another company that recently won FDA
approval for its LED-based device, is
Virginia-based Light BioScience, for its
GentleWaves Photomodulation system.
This uses infrared to plump up and reju-
venate skin cells, particularly around the
eyes, to get rid of crows’ feet and sun-
damaged skin.
High power lasers have been part of the
surgeons’ toolkit for decades, but technol-
ogy improvements and surgical 
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procedure are improving patients’ out-
comes dramatically. For example, a new
through-the-mouth laser procedure, devel-
oped at New York’s Montefiore Medical
Center, allows surgeons to cut away can-
cers on the larynx.This saves not only the
patients’ voice box, by avoiding a tra-
cheotomy, but avoids debilitating rounds
of radiation and chemotherapy.
Meanwhile, researchers at the University
of Texas have used a 200-femtosecond
pulse commercial laser for intracellular
surgery. Using special focusing equip-
ment, surgeons used the laser ‘nanoscis-
sors’ to cut the 300nm neural axon in a
roundworm’s nerve cell without damag-
ing surrounding tissue (see Figure 3).
Curiously, the cell regrew the axon in 24
hours. Researchers are using this laser
tool to study genetic, cellular and molec-
ular processes for nerve regeneration.
As the population ages, and if people
take more vigorous exercise, joint
replacements numbers are likely to rise.
B Braun, a German medical systems sup-
plier, has developed a leg joint imaging
system, based on IR transmitters, rather
than costly CT scans or X-rays.As the sur-
geon adjusts the limb, an infrared camera
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Photodynamic therapy (PDT) is approved in Canada,
Japan, Holland, and US for patients with certain types
of cancer, involving the lung, bladder, and esophagus.
Like PUVA therapy (psoralen ultraviolet ) it sources from
laser or LED arrays. Light is directed through fiber optic
cables to areas inside the body, as when a fiber optic
cable can be inserted through an endoscope (into the
lungs or esophagus) to treat cancer. LEDs are more used
for surface tumors. The FDA has approved Verteporfin
used in conjunction with PDT for those with wet macu-
lar degeneration of retinas. Porfimer sodium, or
Photofrin with PDT, treats or relieves lung or esophagus
cancer systems. 
Researchers continue to study how to improve PDT
effectiveness and expand it to other cancers. In recent
development a team at Scotland’s University of
Strathclyde and Finland’s Optoelectronics Research
Centre have made what is believed to be the first high-
power VECSEL to emit directly at visible wavelengths. 
It emits a continuous wave and currently produces a
maximum output power of 390mW at 674nm. Power
scaling too, in excess of 1W is believed possible and the
device is tunable by 10nm around 674nm. PDT requires
high-power tunable sources at red wavelengths and a
tuning range that covers a number of atomic transitions
used in atom optics.
The VECSEL device was grown on a GaAs substrate 
by MBE. The gain region contains 20 GaInP compres-
sively-strained QW, separated by AlGaInP barrier layers.
The VECSEL was then bonded to a diamond heat-
spreader. The standard cavity contains the gain struc-
ture, a high-reflector folding mirror and a plane output
coupler. Output is tuned with a birefringent filter,
added into the cavity, and rotated to adjust emission
wavelength.
The researchers look to extend the wavelength into the
635-670nm range and the UV. The size of the system
could also be reduced using multi-watt GaN diode lasers
to pump the VECSEL. 
PDT call for lasers
tracks the movements of transmitters
attached to the patient’s leg and relays
the data to a computer.After analysing
positions, and calculating the proper
coordinates it creates a 3-D anatomic
drawing of the joint.This includes all rel-
evant angles, axes and distances, so the
surgeon can locate the replacement joint
precisely and balance the soft tissues.
With some 44% of knee replacements
requiring extra surgery to fine-tune the
procedure, getting it right first time will
be welcomed by 500,000 patients/year.
But one of the most stunning applica-
tions lurks in a patent awarded in 1999
to Houston University’s Alex Ignatiev and
NaiJuan Wu.This is for an artificial eye.
Patent no: 671408 describes “a method
for treating retinal damage by implanting
a thin film optical detector based on a
dielectric capacitor.When illuminated,
the dielectric capacitor generates an
electrical field that replaces signals from
damaged retinal photoreceptors in the
eye.The generated electric field stimu-
lates healthy local nerve endings and are
perceived by the patient as light.”
The co-inventors suggest the thin film be
made from PbZrTiO3, BaSrTiO3,
BaVMnO3 or nitrides such as BN.
Monitor and enlighten
The ability to make compound devices so
small they exhibit quantum behaviours
means that they could be deployed every-
where to monitor and report changes in
almost any environment. Possible health-
care applications include the detection of
pathogens in wards and operating the-
atres, wound management, diagnosis and
responses to therapy.
QDs could be incorporated in paint, in
dressings, in drugs, activated using IR
sources to give an instant reading on the
site’s (non-visible) condition.
Scientists at the Lawrence Livermore
National Laboratory have developed a
range of silicon and germanium QDs that
emit light ranging from the infrared to
the ultraviolet.“What makes our dots
unique,” says the Lab’s Howard Lee,“is
that their luminescence can be tuned to
any wavelength over a broad spectral
range and be stable under ambient condi-
tions.” This includes white light, leading
to cool LED-based lighting transforming
the visual inspection of internal organs.
Research figures suggest for biology and
medicine, a market for stand-alone QDs
in 2005 of $13m, will reach $37.2m by
‘09.The market for QD instruments, com-
ing in ‘06, is expected at $156m by ‘09.
For compound semiconductors, joining
the dots means reaching that market.
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